Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elimusertib in advanced solid tumors and lymphomas
NCT03188965Phase 1Completed
- Sponsor
- Bayer
- Start
- Jul 2017
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of elimusertib in solid tumor, non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL) (5 arms), sponsored by Bayer. Primary endpoints: Maximum Tolerated Dose and / or Recommended Phase II Dose up to 6 months, Incidence of Dose-Limiting Toxicities and 3 more. Started Jul 2017; status: completed.
02
Drugs
elimusertib
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03188965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03188965.